Stocks · News reference
https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-enfortumab-vedotin-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survivalAstraZeneca’s supplemental Biologics License
Ionis Pharmaceuticals announced positive phase III results for two partnered programs: ulefnersen (FUSION study) for FUS-ALS met its primary endpoint with Otsuka planning regulatory discussions, and sefaxersen (IMAgINATION study) for IgAN showed statistically significant proteinuria reductions with Roche continuing the trial. These wins come after recent clinical setbacks in cardiovascular programs but follow FDA approval of Zanvastro for Alexander disease.
The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.